Paper: Accelerated Stability Studies with pMDIs of Respitab HFA-152a Propellant Dispersible Salbutamol Tablets
Rachael Kay is a Project Manager at i2c Pharmaceutical services, a leading service provider for development of pharmaceutical formulations and inhalation devices. Rachael graduated from Cardiff University with a Biological Sciences Degree and joined i2c in 2019 as a research scientist. She focused mainly on formulation and development of pressurized metered dose inhaler products. In 2021, she completed the official project management institute course to fulfil the role of project manager at i2c. Rachael is the lead scientist for the development of i2c’s patented pMDI technology, Respitab. Her main area of research is the development, characterization and optimization of the pMDI technology. She has significant expertise in a range of analytical techniques and is proficient in conducting tests to characterize inhalation products in line with regulatory guidance.